These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 11785834)

  • 1. Engineered antibody for treating lymphoma.
    Stevenson GT; Anderson VA; Leong WS
    Recent Results Cancer Res; 2002; 159():104-12. PubMed ID: 11785834
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Thioether-bonded constructs of Fab'gamma and Fc gamma modules utilizing differential reduction of interchain disulfide bonds.
    Kan KS; Anderson VA; Leong WS; Smith AM; Worth AT; Stevenson GT
    J Immunol; 2001 Jan; 166(2):1320-6. PubMed ID: 11145716
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A standardized conversion of IgG antibody to bispecific form with inversely altered affinities for Fcγ-receptors II and III.
    Leong WS; Thomas KA; Chan CH; Stevenson GT
    Mol Immunol; 2011 Feb; 48(5):760-8. PubMed ID: 21196049
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Potent in vitro and in vivo activity of an Fc-engineered anti-CD19 monoclonal antibody against lymphoma and leukemia.
    Horton HM; Bernett MJ; Pong E; Peipp M; Karki S; Chu SY; Richards JO; Vostiar I; Joyce PF; Repp R; Desjarlais JR; Zhukovsky EA
    Cancer Res; 2008 Oct; 68(19):8049-57. PubMed ID: 18829563
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumour cell killing using chemically engineered antibody constructs specific for tumour cells and the complement inhibitor CD59.
    Harris CL; Kan KS; Stevenson GT; Morgan BP
    Clin Exp Immunol; 1997 Feb; 107(2):364-71. PubMed ID: 9030877
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Initial trial of bispecific antibody-mediated immunotherapy of CD15-bearing tumors: cytotoxicity of human tumor cells using a bispecific antibody comprised of anti-CD15 (MoAb PM81) and anti-CD64/Fc gamma RI (MoAb 32).
    Ball ED; Guyre PM; Mills L; Fisher J; Dinces NB; Fanger MW
    J Hematother; 1992; 1(1):85-94. PubMed ID: 1365020
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An engineered Fc variant of an IgG eliminates all immune effector functions via structural perturbations.
    Vafa O; Gilliland GL; Brezski RJ; Strake B; Wilkinson T; Lacy ER; Scallon B; Teplyakov A; Malia TJ; Strohl WR
    Methods; 2014 Jan; 65(1):114-26. PubMed ID: 23872058
    [TBL] [Abstract][Full Text] [Related]  

  • 8. G-CSF-stimulated PMN in immunotherapy of breast cancer with a bispecific antibody to Fc gamma RI and to HER-2/neu (MDX-210).
    Repp R; Valerius T; Wieland G; Becker W; Steininger H; Deo Y; Helm G; Gramatzki M; Van de Winkel JG; Lang N
    J Hematother; 1995 Oct; 4(5):415-21. PubMed ID: 8581378
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Simultaneous exposure to FcγR and FcαR on monocytes and macrophages enhances antitumor activity in vivo.
    Li B; Xu L; Tao F; Xie K; Wu Z; Li Y; Li J; Chen K; Pi C; Mendelsohn A; Larrick JW; Gu H; Fang J
    Oncotarget; 2017 Jun; 8(24):39356-39366. PubMed ID: 28454118
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Myeloid cells as effector cells for monoclonal antibody therapy of cancer.
    Braster R; O'Toole T; van Egmond M
    Methods; 2014 Jan; 65(1):28-37. PubMed ID: 23811299
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bispecific F(ab'gamma)3 antibody derivatives for redirecting unprimed cytotoxic T cells.
    Tutt A; Greenman J; Stevenson GT; Glennie MJ
    Eur J Immunol; 1991 Jun; 21(6):1351-8. PubMed ID: 1828423
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Engineered human antibodies for the opsonization and killing of
    Chen X; Schneewind O; Missiakas D
    Proc Natl Acad Sci U S A; 2022 Jan; 119(4):. PubMed ID: 35058363
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Conjugation of human Fc gamma in closed-hinge or open-hinge configuration to Fab'gamma and analogous ligands.
    Stevenson GT; Anderson VA; Kan KS; Worth AT
    J Immunol; 1997 Mar; 158(5):2242-50. PubMed ID: 9036971
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A chimeric antibody with dual Fc regions (bisFabFc) prepared by manipulations at the IgG hinge.
    Stevenson GT; Pindar A; Slade CJ
    Anticancer Drug Des; 1989 Mar; 3(4):219-30. PubMed ID: 2930624
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fc optimization of therapeutic antibodies enhances their ability to kill tumor cells in vitro and controls tumor expansion in vivo via low-affinity activating Fcgamma receptors.
    Stavenhagen JB; Gorlatov S; Tuaillon N; Rankin CT; Li H; Burke S; Huang L; Vijh S; Johnson S; Bonvini E; Koenig S
    Cancer Res; 2007 Sep; 67(18):8882-90. PubMed ID: 17875730
    [TBL] [Abstract][Full Text] [Related]  

  • 16. IgG Fc domains that bind C1q but not effector Fcγ receptors delineate the importance of complement-mediated effector functions.
    Lee CH; Romain G; Yan W; Watanabe M; Charab W; Todorova B; Lee J; Triplett K; Donkor M; Lungu OI; Lux A; Marshall N; Lindorfer MA; Goff OR; Balbino B; Kang TH; Tanno H; Delidakis G; Alford C; Taylor RP; Nimmerjahn F; Varadarajan N; Bruhns P; Zhang YJ; Georgiou G
    Nat Immunol; 2017 Aug; 18(8):889-898. PubMed ID: 28604720
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bispecific antibody-dependent cellular cytotoxicity of HER2/neu-overexpressing tumor cells by Fc gamma receptor type I-expressing effector cells.
    Keler T; Graziano RF; Mandal A; Wallace PK; Fisher J; Guyre PM; Fanger MW; Deo YM
    Cancer Res; 1997 Sep; 57(18):4008-14. PubMed ID: 9307286
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Engineered antibody Fc variants with enhanced effector function.
    Lazar GA; Dang W; Karki S; Vafa O; Peng JS; Hyun L; Chan C; Chung HS; Eivazi A; Yoder SC; Vielmetter J; Carmichael DF; Hayes RJ; Dahiyat BI
    Proc Natl Acad Sci U S A; 2006 Mar; 103(11):4005-10. PubMed ID: 16537476
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An Fc engineering approach that modulates antibody-dependent cytokine release without altering cell-killing functions.
    Kinder M; Greenplate AR; Strohl WR; Jordan RE; Brezski RJ
    MAbs; 2015; 7(3):494-504. PubMed ID: 25933349
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tandemly repeated Fc domain augments binding avidities of antibodies for Fcgamma receptors, resulting in enhanced antibody-dependent cellular cytotoxicity.
    Nagashima H; Tezuka T; Tsuchida W; Maeda H; Kohroki J; Masuho Y
    Mol Immunol; 2008 May; 45(10):2752-63. PubMed ID: 18353438
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.